GlassScriptPhysician profile
Kevin Schlamp
NPI 1336133677
$4,468.23
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $551 · 2021: $996 · 2022: $1,060 · 2023: $958 · 2024: $84.55.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,043.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,042.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,009.50 | 2021-2023 | Vraylar, Qulipta, Ubrelvy |
| Lilly USA, LLC | $702.95 | 2019-2023 | Mounjaro |
| Novo Nordisk INC | $482.03 | 2019-2023 | Wegovy |
| Pfizer INC. | $305.79 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $241.58 | 2019-2023 | Breztri, Airsupra |
| Glaxosmithkline, LLC. | $234.45 | 2020-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $233.49 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Amarin Pharma, INC. | $150.07 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $121.11 | 2022 | |
| Intuitive Surgical, INC. | $115.96 | 2019 | |
| Dexcom, INC. | $111.10 | 2021 | |
| Janssen Pharmaceuticals, INC | $76.15 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $70.22 | 2022-2023 | |
| Esperion Therapeutics, INC. | $65.93 | 2020-2021 | |
| Amgen INC. | $59.32 | 2020-2023 | Repatha, Otezla |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $56.11 | 2022-2023 | |
| Allergan, INC. | $51.78 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.68 | 2020-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $48.46 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.04 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $32.68 | 2023 | Quviviq |
| Abbott Laboratories | $30.25 | 2021-2022 | |
| Astellas Pharma US INC | $29.94 | 2019-2020 | |
| Linus Health, INC. | $28.58 | 2023 | |
| Gilead Sciences, INC. | $20.45 | 2021 | |
| Exact Sciences Corporation | $17.81 | 2023 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $17.39 | 2024 | Voquezna |
| Kowa Pharmaceuticals America, INC. | $16.55 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $13.91 | 2021 | |
| Daiichi Sankyo INC. | $13.79 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.16 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Schlamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.